Li-Jun Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li-Jun Hou has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Guang Huang
Department of Neurosurgery, Changzheng Hospital-Second Military Medical University, Shanghai, China
4 shared publications - Chun Luo
Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
4 shared publications - Guo-Han Hu
Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China
4 shared publications Xiang Wang
Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China
4 shared publicationsPing Sheng
Department of Neurosurgery, Shanghai Institute of Neurosurgery, PLA Institute of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China ; Neuroscience Center, Changzheng Hospital, Second Military Medical University, Shanghai, China
3 shared publicationsYan Dong
Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China
3 shared publications
Latest Publications
- 1 March 2014
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 42 (2) , 132-140
Endoscopic transmaxillary transMüller's muscle approach for decompression of superior orbital fissure: A cadaveric study with illustrative case
- 1 March 2014
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 42 (2) , 132-140
Endoscopic transmaxillary transMüller's muscle approach for decompression of superior orbital fissure: A cadaveric study with illustrative case
- Open Access
- 8 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e84391
Effect of Methylphenidate in Patients with Cancer-Related Fatigue: A Systematic Review and Meta-Analysis
Cancer-related fatigue (CRF) is a common symptom affecting patients with cancer. There are an increasing number of trials examining potential treatments for CRF. Methylphenidate represents one of the most researched drugs and an up-to-date assessment of the evidence for its use is needed. Trials of methylphenidate for CRF provided inconsistent results. This meta-analysis was aimed at assessing the effect and safety of methylphenidate on CRF. We comprehensively searched the Pubmed, EMBASE, PSYCHInfo and the Cochrane databases in order to identify published studies on the effect of methylphenidate on CRF. Primary outcomes included fatigue. Secondary outcomes included depression, cognition and adverse effects. A meta-analysis was conducted on five randomized controlled trials and 498 patients were enrolled. Despite a large placebo effect observed in the studies included, pooled data suggested therapeutic effect of methylphenidate on CRF. Subgroup Analyses showed that the efficacy of methylphenidate on CRF is getting better with prolonging treatment duration, with a MD of −3.70 (95% CI −7.03– −0.37, p = 0.03) for long-time group and a MD of −2.49 (95% CI −6.01–1.03, p = 0.17) for short-time group. In general, there was no impact of methylphenidate on depression and cognition associated with CRF. Adverse events were similar between methylphenidate and placebo groups except that more patients reported vertigo, anxiety, anorexia and nausea in methylphenidate group compared to placebo group. Existing trials of methylphenidate on CRF provided limited evidence for the use of methylphenidate to treat CRF. The absolute numbers still remain small, and further confirmation is needed before firm recommendations on their usage and safety can be made in the treatment of CRF.
- 8 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e84391
Open AccessEffect of Methylphenidate in Patients with Cancer-Related Fatigue: A Systematic Review and Meta-Analysis
Cancer-related fatigue (CRF) is a common symptom affecting patients with cancer. There are an increasing number of trials examining potential treatments for CRF. Methylphenidate represents one of the most researched drugs and an up-to-date assessment of the evidence for its use is needed. Trials of methylphenidate for CRF provided inconsistent results. This meta-analysis was aimed at assessing the effect and safety of methylphenidate on CRF. We comprehensively searched the Pubmed, EMBASE, PSYCHInfo and the Cochrane databases in order to identify published studies on the effect of methylphenidate on CRF. Primary outcomes included fatigue. Secondary outcomes included depression, cognition and adverse effects. A meta-analysis was conducted on five randomized controlled trials and 498 patients were enrolled. Despite a large placebo effect observed in the studies included, pooled data suggested therapeutic effect of methylphenidate on CRF. Subgroup Analyses showed that the efficacy of methylphenidate on CRF is getting better with prolonging treatment duration, with a MD of −3.70 (95% CI −7.03– −0.37, p = 0.03) for long-time group and a MD of −2.49 (95% CI −6.01–1.03, p = 0.17) for short-time group. In general, there was no impact of methylphenidate on depression and cognition associated with CRF. Adverse events were similar between methylphenidate and placebo groups except that more patients reported vertigo, anxiety, anorexia and nausea in methylphenidate group compared to placebo group. Existing trials of methylphenidate on CRF provided limited evidence for the use of methylphenidate to treat CRF. The absolute numbers still remain small, and further confirmation is needed before firm recommendations on their usage and safety can be made in the treatment of CRF.
- Open Access
- 1 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e76087
Risk Factors Associated with Sleep Disturbance following Traumatic Brain Injury: Clinical Findings and Questionnaire Based Study
Sleep disturbance is very common following traumatic brain injury (TBI), which may initiate or exacerbate a variety of co-morbidities and negatively impact rehabilitative treatments. To date, there are paradoxical reports regarding the associations between inherent characteristics of TBI and sleep disturbance in TBI population. The current study was designed to explore the relationship between the presence of sleep disturbance and characteristics of TBI and identify the factors which are closely related to the presence of sleep disturbance in TBI population. 98 TBI patients (72 males, mean age ± SD, 47 ± 13 years, range 18-70) were recruited. Severity of TBI was evaluated based on Glasgow Coma Scale (GCS). All participants performed cranial computed tomography and were examined on self-reported sleep quality, anxiety, and depression. TBI was mild in 69 (70%), moderate in 15 (15%) and severe in 14 (15%) patients. 37 of 98 patients (38%) reported sleep disturbance following TBI. Insomnia was diagnosed in 28 patients (29%) and post-traumatic hypersomnia in 9 patients (9%). In TBI with insomnia group, 5 patients (18%) complained of difficulty falling asleep only, 8 patients (29%) had difficulty maintaining sleep without difficulty in initial sleep and 15 patients (53%) presented both difficulty falling asleep and difficulty maintaining sleep. Risk factors associated with insomnia were headache and/or dizziness and more symptoms of anxiety and depression rather than GCS. In contrast, GCS was independently associated with the presence of hypersomnia following TBI. Furthermore, there was no evidence of an association between locations of brain injury and the presence of sleep disturbance after TBI. Our data support and contribute to a growing body of evidence which indicates that TBI patients with insomnia are prone to suffer from concomitant headache and/or dizziness, report more symptoms of anxiety and depression and severe TBI patients are likely to experience hypersomnia.
- 1 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e76087
Open AccessRisk Factors Associated with Sleep Disturbance following Traumatic Brain Injury: Clinical Findings and Questionnaire Based Study
Sleep disturbance is very common following traumatic brain injury (TBI), which may initiate or exacerbate a variety of co-morbidities and negatively impact rehabilitative treatments. To date, there are paradoxical reports regarding the associations between inherent characteristics of TBI and sleep disturbance in TBI population. The current study was designed to explore the relationship between the presence of sleep disturbance and characteristics of TBI and identify the factors which are closely related to the presence of sleep disturbance in TBI population. 98 TBI patients (72 males, mean age ± SD, 47 ± 13 years, range 18-70) were recruited. Severity of TBI was evaluated based on Glasgow Coma Scale (GCS). All participants performed cranial computed tomography and were examined on self-reported sleep quality, anxiety, and depression. TBI was mild in 69 (70%), moderate in 15 (15%) and severe in 14 (15%) patients. 37 of 98 patients (38%) reported sleep disturbance following TBI. Insomnia was diagnosed in 28 patients (29%) and post-traumatic hypersomnia in 9 patients (9%). In TBI with insomnia group, 5 patients (18%) complained of difficulty falling asleep only, 8 patients (29%) had difficulty maintaining sleep without difficulty in initial sleep and 15 patients (53%) presented both difficulty falling asleep and difficulty maintaining sleep. Risk factors associated with insomnia were headache and/or dizziness and more symptoms of anxiety and depression rather than GCS. In contrast, GCS was independently associated with the presence of hypersomnia following TBI. Furthermore, there was no evidence of an association between locations of brain injury and the presence of sleep disturbance after TBI. Our data support and contribute to a growing body of evidence which indicates that TBI patients with insomnia are prone to suffer from concomitant headache and/or dizziness, report more symptoms of anxiety and depression and severe TBI patients are likely to experience hypersomnia.
- Open Access
- 25 July 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , 234-11
Clinical review: Efficacy of antimicrobial-impregnated catheters in external ventricular drainage - a systematic review and meta-analysis
To assess the efficacy of antimicrobial-impregnated catheters in preventing catheter-related infections during external ventricular drainage (EVD), we performed a meta-analysis and systematic review. We systematically searched Medline, Embase, and the Cochrane Library. All randomized controlled trials (RCTs) and nonrandomized prospective studies (NPSs) related to antimicrobial-impregnated EVD catheters were included. The primary outcome was the rate of cerebrospinal fluid infection (CFI). The secondary outcomes included the rate of time-dependent CFI and catheter bacterial colonization. We further performed subgroup analysis, meta-regression analysis, and microbial spectrum analysis. Four RCTs and four NPSs were included. The overall rate of CFIs was 3.6% in the antimicrobial-impregnated catheter group and 13.7% in the standard catheter group. The pooled data demonstrated that antimicrobial-impregnated catheters were superior to standard catheters in lowering the rate of CFIs (odds ratio (OR) = 0.25, 95% confidence interval (CI) = 0.12 to 0.52, P <0.05). In survival analysis, the 20-day infection rate was significantly reduced with the use of antimicrobial-impregnated catheters (hazard ratio = 0.52, 95% CI = 0.29 to 0.95, P <0.05). Furthermore, a significantly decreased rate of catheter bacterial colonization was noticed for antimicrobial-impregnated catheters (OR = 0.37, 95% CI = 0.21 to 0.64, P <0.05). In subgroup analyses, although significant results remained for RCTs and NPSs, a subgroup difference was revealed (P <0.05). Compared with standard catheters, a significantly lower rate of CFIs was noticed for clindamycin/rifampin-impregnated catheters (OR = 0.27, 95% CI = 0.10 to 0.73, P <0.05) and for minocycline/rifampin-impregnated catheters (OR = 0.11, 95% CI = 0.06 to 0.21, P <0.05). However, no statistical significance was found when compared with silver-impregnated catheters (OR = 0.33, 95% CI = 0.07 to 1.69, P = 0.18). In microbial spectrum analysis, antimicrobial-impregnated catheters were shown to have a lower rate of Gram-positive bacterial infection, particularly the coagulase-negative Staphylococcus. In conclusion, the use of antimicrobial-impregnated EVD catheters could be beneficial for the prevention of CFI and catheter bacterial colonization. Although antibiotic-coated catheters seem to be effective, no sufficient evidence supports the efficacy of silver-impregnated catheters.
- 25 July 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , 234-11
Open AccessClinical review: Efficacy of antimicrobial-impregnated catheters in external ventricular drainage - a systematic review and meta-analysis
To assess the efficacy of antimicrobial-impregnated catheters in preventing catheter-related infections during external ventricular drainage (EVD), we performed a meta-analysis and systematic review. We systematically searched Medline, Embase, and the Cochrane Library. All randomized controlled trials (RCTs) and nonrandomized prospective studies (NPSs) related to antimicrobial-impregnated EVD catheters were included. The primary outcome was the rate of cerebrospinal fluid infection (CFI). The secondary outcomes included the rate of time-dependent CFI and catheter bacterial colonization. We further performed subgroup analysis, meta-regression analysis, and microbial spectrum analysis. Four RCTs and four NPSs were included. The overall rate of CFIs was 3.6% in the antimicrobial-impregnated catheter group and 13.7% in the standard catheter group. The pooled data demonstrated that antimicrobial-impregnated catheters were superior to standard catheters in lowering the rate of CFIs (odds ratio (OR) = 0.25, 95% confidence interval (CI) = 0.12 to 0.52, P <0.05). In survival analysis, the 20-day infection rate was significantly reduced with the use of antimicrobial-impregnated catheters (hazard ratio = 0.52, 95% CI = 0.29 to 0.95, P <0.05). Furthermore, a significantly decreased rate of catheter bacterial colonization was noticed for antimicrobial-impregnated catheters (OR = 0.37, 95% CI = 0.21 to 0.64, P <0.05). In subgroup analyses, although significant results remained for RCTs and NPSs, a subgroup difference was revealed (P <0.05). Compared with standard catheters, a significantly lower rate of CFIs was noticed for clindamycin/rifampin-impregnated catheters (OR = 0.27, 95% CI = 0.10 to 0.73, P <0.05) and for minocycline/rifampin-impregnated catheters (OR = 0.11, 95% CI = 0.06 to 0.21, P <0.05). However, no statistical significance was found when compared with silver-impregnated catheters (OR = 0.33, 95% CI = 0.07 to 1.69, P = 0.18). In microbial spectrum analysis, antimicrobial-impregnated catheters were shown to have a lower rate of Gram-positive bacterial infection, particularly the coagulase-negative Staphylococcus. In conclusion, the use of antimicrobial-impregnated EVD catheters could be beneficial for the prevention of CFI and catheter bacterial colonization. Although antibiotic-coated catheters seem to be effective, no sufficient evidence supports the efficacy of silver-impregnated catheters.
- Open Access
- 19 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e58838
Nutritional Support for Patients Sustaining Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prospective Studies
In traumatic brain injury (TBI), the appropriate timing and route of feeding, and the efficacy of immune-enhancing formulae have not been well established. We performed this meta-analysis aiming to compare the effects of different nutritional support modalities on clinical outcomes of TBI patients. We systematically searched Pubmed, Embase, and the Cochrane Library until October, 2012. All randomized controlled trials (RCTs) and non-randomized prospective studies (NPSs) that compared the effects of different routes, timings, or formulae of feeding on outcomes in TBI patients were selected. The primary outcomes included mortality and poor outcome. The secondary outcomes included the length of hospital stay, the length of ventilation days, and the rate of infectious or feeding-related complications. 13 RCTs and 3 NPSs were included. The pooled data demonstrated that, compared with delayed feeding, early feeding was associated with a significant reduction in the rate of mortality (relative risk [RR] = 0.35; 95% CI, 0.24–0.50), poor outcome (RR = 0.70; 95% CI, 0.54–0.91), and infectious complications (RR = 0.77; 95% CI, 0.59–0.99). Compared with enteral nutrition, parenteral nutrition showed a slight trend of reduction in the rate of mortality (RR = 0.61; 95% CI, 0.34–1.09), poor outcome (RR = 0.73; 95% CI, 0.51–1.04), and infectious complications (RR = 0.89; 95% CI, 0.66–1.22), whereas without statistical significances. The immune-enhancing formula was associated with a significant reduction in infection rate compared with the standard formula (RR = 0.54; 95% CI, 0.35–0.82). Small-bowel feeding was found to be with a decreasing rate of pneumonia compared with nasogastric feeding (RR = 0.41; 95% CI, 0.22–0.76). After TBI, early initiation of nutrition is recommended. It appears that parenteral nutrition is superior to enteral nutrition in improving outcomes. Our results lend support to the use of small-bowel feeding and immune-enhancing formulae in reducing infectious complications.
- 19 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e58838
Open AccessNutritional Support for Patients Sustaining Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prospective Studies
In traumatic brain injury (TBI), the appropriate timing and route of feeding, and the efficacy of immune-enhancing formulae have not been well established. We performed this meta-analysis aiming to compare the effects of different nutritional support modalities on clinical outcomes of TBI patients. We systematically searched Pubmed, Embase, and the Cochrane Library until October, 2012. All randomized controlled trials (RCTs) and non-randomized prospective studies (NPSs) that compared the effects of different routes, timings, or formulae of feeding on outcomes in TBI patients were selected. The primary outcomes included mortality and poor outcome. The secondary outcomes included the length of hospital stay, the length of ventilation days, and the rate of infectious or feeding-related complications. 13 RCTs and 3 NPSs were included. The pooled data demonstrated that, compared with delayed feeding, early feeding was associated with a significant reduction in the rate of mortality (relative risk [RR] = 0.35; 95% CI, 0.24–0.50), poor outcome (RR = 0.70; 95% CI, 0.54–0.91), and infectious complications (RR = 0.77; 95% CI, 0.59–0.99). Compared with enteral nutrition, parenteral nutrition showed a slight trend of reduction in the rate of mortality (RR = 0.61; 95% CI, 0.34–1.09), poor outcome (RR = 0.73; 95% CI, 0.51–1.04), and infectious complications (RR = 0.89; 95% CI, 0.66–1.22), whereas without statistical significances. The immune-enhancing formula was associated with a significant reduction in infection rate compared with the standard formula (RR = 0.54; 95% CI, 0.35–0.82). Small-bowel feeding was found to be with a decreasing rate of pneumonia compared with nasogastric feeding (RR = 0.41; 95% CI, 0.22–0.76). After TBI, early initiation of nutrition is recommended. It appears that parenteral nutrition is superior to enteral nutrition in improving outcomes. Our results lend support to the use of small-bowel feeding and immune-enhancing formulae in reducing infectious complications.
- 20 January 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (1) , 72-77
Pathogenesis of traumatic brain injury-associated coagulopathy: a review
- 20 January 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (1) , 72-77
Pathogenesis of traumatic brain injury-associated coagulopathy: a review
- 20 November 2012
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 32 (11) , 1253-1256
Sleep disorders after traumatic brain injury
- 20 November 2012
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 32 (11) , 1253-1256
Sleep disorders after traumatic brain injury
- Open Access
- 17 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47778
Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials
Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (aSAH). Clazosentan, a selective endothelinreceptor antagonist, has been suggested to help reduce the incidence of vasospasm in patients with aSAH. However, the results were controversial in previous trials. This meta-analysis attempts to assess the effect of clazosentan in patients with aSAH. We systematically searched Pubmed, Embase, and the Cochrane Library from their inception until June, 2012. All randomized controlled trials (RCTs) related to the effect of clazosentan in aSAH were included. The primary outcomes included the incidence of angiographic vasospasm, new cerebral infarction (NCI), delayed ischemic neurological deficits (DIND), and vasospasm-related morbidity/mortality (M/M); the second outcomes included the occurrence of rescue therapy, all-cause-mortality, and poor outcome. 4 RCTs were included with a total of 2156 patients. The risk of angiographic vasospasm (relative risk [RR] = 0.58; 95% CI, 0.48 to 0.71), DIND (RR = 0.76; 95% CI, 0.62 to 0.92), and vasospasm-related M/M (RR = 0.80; 95% CI, 0.67 to 0.96) were statistically significantly reduced in the clazosentan group. Patients treated with clazosentan had a reduced occurrence of rescue therapy (RR = 0.62; 95% CI, 0.49 to 0.79). However, no statistically significant effects were observed in NCI (RR = 0.74; 95% CI, 0.52 to 1.04), mortality (RR = 1.03; 95% CI, 0.71 to 1.49), and poor outcome (RR = 1.12; 95% CI, 0.96 to 1.30). Our pooling data supports that clazosentan is probably effective in preventing the occurrence of angiographic vasospasm, vasospasm-related DIND, vasospasm related M/M, and rescue therapy. However, no evidence lends significant supports to the benefits of clazosentan in decreasing the occurrence of NCI, mortality or improving the functional outcome.
- 17 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47778
Open AccessEffect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials
Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (aSAH). Clazosentan, a selective endothelinreceptor antagonist, has been suggested to help reduce the incidence of vasospasm in patients with aSAH. However, the results were controversial in previous trials. This meta-analysis attempts to assess the effect of clazosentan in patients with aSAH. We systematically searched Pubmed, Embase, and the Cochrane Library from their inception until June, 2012. All randomized controlled trials (RCTs) related to the effect of clazosentan in aSAH were included. The primary outcomes included the incidence of angiographic vasospasm, new cerebral infarction (NCI), delayed ischemic neurological deficits (DIND), and vasospasm-related morbidity/mortality (M/M); the second outcomes included the occurrence of rescue therapy, all-cause-mortality, and poor outcome. 4 RCTs were included with a total of 2156 patients. The risk of angiographic vasospasm (relative risk [RR] = 0.58; 95% CI, 0.48 to 0.71), DIND (RR = 0.76; 95% CI, 0.62 to 0.92), and vasospasm-related M/M (RR = 0.80; 95% CI, 0.67 to 0.96) were statistically significantly reduced in the clazosentan group. Patients treated with clazosentan had a reduced occurrence of rescue therapy (RR = 0.62; 95% CI, 0.49 to 0.79). However, no statistically significant effects were observed in NCI (RR = 0.74; 95% CI, 0.52 to 1.04), mortality (RR = 1.03; 95% CI, 0.71 to 1.49), and poor outcome (RR = 1.12; 95% CI, 0.96 to 1.30). Our pooling data supports that clazosentan is probably effective in preventing the occurrence of angiographic vasospasm, vasospasm-related DIND, vasospasm related M/M, and rescue therapy. However, no evidence lends significant supports to the benefits of clazosentan in decreasing the occurrence of NCI, mortality or improving the functional outcome.
- 20 June 2011
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 31 (6) , 598-602
Construction of lentiviral vector for RNA interference of Id2 gene and its effect on proliferation and apoptosis of gliomas cell line in vitro
Objective To construct a lentiviral vector carrying short hairpin RNA(shRNA) of human Id2 gene and to investigate its effect on the proliferation and apoptosis in glioma cell line U251.Methods Four shRNA sequences targeting human Id2 gene were designed and synthesized.The shRNAs were inserted into the pGCSIL-GFP lentiviral vector.Id2 sequence was amplified from the plasmid which contained Id2 gene as verified by PCR,and was inserted into the pEGFP-N1-3FLAG vector.Lentiviral vector for RNAi of Id2 was constructed and was used to infect 293T cells.The infection efficiency was evaluated and then the lentiviral vector was used to infect U251 cell line.Western blotting analysis was employed to assess the gene silencing efficiency.Cell proliferation was tested by MTT.Cell apoptosis was observed by RT-PCR analysis of caspase 3 expression in U251 cells after infection.Results The results of PCR analysis and DNA sequencing agreed to each other.Compared with the control group,the transfected U251 cells had significantly decreased cell proliferation,and increased apoptosis rate and caspase 3 expression(P<0.05).Conclusion We have successfully constructed lentivirus RNAi vector of Id2,which can inhibit the proliferation and promote the apoptosis of glioma cells in vitro.
- 20 June 2011
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 31 (6) , 598-602
Construction of lentiviral vector for RNA interference of Id2 gene and its effect on proliferation and apoptosis of gliomas cell line in vitro
Objective To construct a lentiviral vector carrying short hairpin RNA(shRNA) of human Id2 gene and to investigate its effect on the proliferation and apoptosis in glioma cell line U251.Methods Four shRNA sequences targeting human Id2 gene were designed and synthesized.The shRNAs were inserted into the pGCSIL-GFP lentiviral vector.Id2 sequence was amplified from the plasmid which contained Id2 gene as verified by PCR,and was inserted into the pEGFP-N1-3FLAG vector.Lentiviral vector for RNAi of Id2 was constructed and was used to infect 293T cells.The infection efficiency was evaluated and then the lentiviral vector was used to infect U251 cell line.Western blotting analysis was employed to assess the gene silencing efficiency.Cell proliferation was tested by MTT.Cell apoptosis was observed by RT-PCR analysis of caspase 3 expression in U251 cells after infection.Results The results of PCR analysis and DNA sequencing agreed to each other.Compared with the control group,the transfected U251 cells had significantly decreased cell proliferation,and increased apoptosis rate and caspase 3 expression(P<0.05).Conclusion We have successfully constructed lentivirus RNAi vector of Id2,which can inhibit the proliferation and promote the apoptosis of glioma cells in vitro.
- 14 August 2009
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 28 (8) , 934-939
Identification and analysis of subtracted cDNA library of differentially expressed genes associated with chronic optic nerve injury
Objective:To clone,identify and analyze subtractive cDNA libraries of differentially expressed genes associated with chronic optic nerve compression in cats.Methods: The constructed cDNA libraries were amplified by E.coli transformation with calcium chloride and were subjected to blue and white screening.Three hundred positive bacterial clones were randomly chosen from each library and were identified by colony PCR.The positive clones were sequenced to screen for the differentially expressed genes.The identified sequences were then analyzed for homology using Blast program against the DNA database bank of Japanese through internet.Real-time PCR was performed to verify the expression of the 4 differential clones.Results: One thousand positive clones were identified by PCR and 674 ESTs were obtained by seqeuncing,with length ranging from 200 to 800bp.Results from Blast analysis revealed 14,20,23 and 19 homolog genes in 4-w forward,4-w reverse,8-w forward and 8-w reverse subtractive libraries,respectively.These genes fell into several functional groups,such as energy and metabolism,ion transport,gene transcription,signal transduction,cellular injury and repair,and MHC molecules.Result of real-time PCR verified that the 4 clones were differentially expressed.Conclusion: The constructed subtractive cDNA libraries lay an experimental basis for further identification and study of the differentially expressed genes related to chronic optic nerve injury.
- 14 August 2009
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 28 (8) , 934-939
Identification and analysis of subtracted cDNA library of differentially expressed genes associated with chronic optic nerve injury
Objective:To clone,identify and analyze subtractive cDNA libraries of differentially expressed genes associated with chronic optic nerve compression in cats.Methods: The constructed cDNA libraries were amplified by E.coli transformation with calcium chloride and were subjected to blue and white screening.Three hundred positive bacterial clones were randomly chosen from each library and were identified by colony PCR.The positive clones were sequenced to screen for the differentially expressed genes.The identified sequences were then analyzed for homology using Blast program against the DNA database bank of Japanese through internet.Real-time PCR was performed to verify the expression of the 4 differential clones.Results: One thousand positive clones were identified by PCR and 674 ESTs were obtained by seqeuncing,with length ranging from 200 to 800bp.Results from Blast analysis revealed 14,20,23 and 19 homolog genes in 4-w forward,4-w reverse,8-w forward and 8-w reverse subtractive libraries,respectively.These genes fell into several functional groups,such as energy and metabolism,ion transport,gene transcription,signal transduction,cellular injury and repair,and MHC molecules.Result of real-time PCR verified that the 4 clones were differentially expressed.Conclusion: The constructed subtractive cDNA libraries lay an experimental basis for further identification and study of the differentially expressed genes related to chronic optic nerve injury.